Research ExplorerPublicationsSurvival and New Prognosticators in Metastatic Seminoma: Res...

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

Standard

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. / Beyer, Jörg; Collette, Laurence; Sauvé, Nicolas; Daugaard, Gedske; Feldman, Darren R; Tandstad, Torgrim; Tryakin, Alexey; Stahl, Olof; Gonzalez-Billalabeitia, Enrique; De Giorgi, Ugo; Culine, Stéphane; de Wit, Ronald; Hansen, Aaron R; Bebek, Marko; Terbuch, Angelika; Albany, Costantine; Hentrich, Marcus; Gietema, Jourik A; Negaard, Helene; Huddart, Robert A; Lorch, Anja; Cafferty, Fay H; Heng, Daniel Y C; Sweeney, Christopher J; Winquist, Eric; Chovanec, Michal; Fankhauser, Christian; Stark, Daniel; Grimison, Peter; Necchi, Andrea; Tran, Ben; Heidenreich, Axel; Shamash, Jonathan; Sternberg, Cora N; Vaughn, David J; Duran, Ignacio; Bokemeyer, Carsten; Patrikidou, Anna; Cathomas, Richard; Assele, Samson; Gillessen, Silke; International Germ Cell Cancer Classification Update Consortium.

In: J CLIN ONCOL, Vol. 39, No. 14, 10.05.2021, p. 1553-1562.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Beyer, J, Collette, L, Sauvé, N, Daugaard, G, Feldman, DR, Tandstad, T, Tryakin, A, Stahl, O, Gonzalez-Billalabeitia, E, De Giorgi, U, Culine, S, de Wit, R, Hansen, AR, Bebek, M, Terbuch, A, Albany, C, Hentrich, M, Gietema, JA, Negaard, H, Huddart, RA, Lorch, A, Cafferty, FH, Heng, DYC, Sweeney, CJ, Winquist, E, Chovanec, M, Fankhauser, C, Stark, D, Grimison, P, Necchi, A, Tran, B, Heidenreich, A, Shamash, J, Sternberg, CN, Vaughn, DJ, Duran, I, Bokemeyer, C, Patrikidou, A, Cathomas, R, Assele, S, Gillessen, S & International Germ Cell Cancer Classification Update Consortium 2021, 'Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium', J CLIN ONCOL, vol. 39, no. 14, pp. 1553-1562. https://doi.org/10.1200/JCO.20.03292

APA

Beyer, J., Collette, L., Sauvé, N., Daugaard, G., Feldman, D. R., Tandstad, T., Tryakin, A., Stahl, O., Gonzalez-Billalabeitia, E., De Giorgi, U., Culine, S., de Wit, R., Hansen, A. R., Bebek, M., Terbuch, A., Albany, C., Hentrich, M., Gietema, J. A., Negaard, H., ... International Germ Cell Cancer Classification Update Consortium (2021). Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. J CLIN ONCOL, 39(14), 1553-1562. https://doi.org/10.1200/JCO.20.03292

Vancouver

Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T et al. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. J CLIN ONCOL. 2021 May 10;39(14):1553-1562. https://doi.org/10.1200/JCO.20.03292

Bibtex

@article{28e0805e58064255a86d42b44aad0431,
title = "Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium",
abstract = "PURPOSE: The classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has been a major advance in the management of germ-cell tumors, but relies on data of only 660 patients with seminoma treated between 1975 and 1990. We re-evaluated this classification in a database from a large international consortium.MATERIALS AND METHODS: Data on 2,451 men with metastatic seminoma treated with cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013 were collected from 30 institutions or collaborative groups in Australia, Europe, and North America. Clinical trial and registry data were included. Primary end points were progression-free survival (PFS) and overall survival (OS) calculated from day 1 of treatment. Variables at initial presentation were evaluated for their prognostic impact. Results were validated in an independent validation set of 764 additional patients.RESULTS: Compared with the initial IGCCCG classification, in our modern series, 5-year PFS improved from 82% to 89% (95% CI, 87 to 90) and 5-year OS from 86% to 95% (95% CI, 94 to 96) in good prognosis, and from 67% to 79% (95% CI, 70 to 85) and 72% to 88% (95% CI, 80 to 93) in intermediate prognosis patients. Lactate dehydrogenase (LDH) proved to be an additional adverse prognostic factor. Good prognosis patients with LDH above 2.5× upper limit of normal had a 3-year PFS of 80% (95% CI, 75 to 84) and a 3-year OS of 92% (95% CI, 88 to 95) versus 92% (95% CI, 90 to 94) and 97% (95% CI, 96 to 98) in the group with lower LDH.CONCLUSION: PFS and OS in metastatic seminoma significantly improved in our modern series compared with the original data. The original IGCCCG classification retains its relevance, but can be further refined by adding LDH at a cutoff of 2.5× upper limit of normal as an additional adverse prognostic factor.",
author = "J{\"o}rg Beyer and Laurence Collette and Nicolas Sauv{\'e} and Gedske Daugaard and Feldman, {Darren R} and Torgrim Tandstad and Alexey Tryakin and Olof Stahl and Enrique Gonzalez-Billalabeitia and {De Giorgi}, Ugo and St{\'e}phane Culine and {de Wit}, Ronald and Hansen, {Aaron R} and Marko Bebek and Angelika Terbuch and Costantine Albany and Marcus Hentrich and Gietema, {Jourik A} and Helene Negaard and Huddart, {Robert A} and Anja Lorch and Cafferty, {Fay H} and Heng, {Daniel Y C} and Sweeney, {Christopher J} and Eric Winquist and Michal Chovanec and Christian Fankhauser and Daniel Stark and Peter Grimison and Andrea Necchi and Ben Tran and Axel Heidenreich and Jonathan Shamash and Sternberg, {Cora N} and Vaughn, {David J} and Ignacio Duran and Carsten Bokemeyer and Anna Patrikidou and Richard Cathomas and Samson Assele and Silke Gillessen and {International Germ Cell Cancer Classification Update Consortium}",
year = "2021",
month = may,
day = "10",
doi = "10.1200/JCO.20.03292",
language = "English",
volume = "39",
pages = "1553--1562",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "14",

}

RIS

TY - JOUR

T1 - Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

AU - Beyer, Jörg

AU - Collette, Laurence

AU - Sauvé, Nicolas

AU - Daugaard, Gedske

AU - Feldman, Darren R

AU - Tandstad, Torgrim

AU - Tryakin, Alexey

AU - Stahl, Olof

AU - Gonzalez-Billalabeitia, Enrique

AU - De Giorgi, Ugo

AU - Culine, Stéphane

AU - de Wit, Ronald

AU - Hansen, Aaron R

AU - Bebek, Marko

AU - Terbuch, Angelika

AU - Albany, Costantine

AU - Hentrich, Marcus

AU - Gietema, Jourik A

AU - Negaard, Helene

AU - Huddart, Robert A

AU - Lorch, Anja

AU - Cafferty, Fay H

AU - Heng, Daniel Y C

AU - Sweeney, Christopher J

AU - Winquist, Eric

AU - Chovanec, Michal

AU - Fankhauser, Christian

AU - Stark, Daniel

AU - Grimison, Peter

AU - Necchi, Andrea

AU - Tran, Ben

AU - Heidenreich, Axel

AU - Shamash, Jonathan

AU - Sternberg, Cora N

AU - Vaughn, David J

AU - Duran, Ignacio

AU - Bokemeyer, Carsten

AU - Patrikidou, Anna

AU - Cathomas, Richard

AU - Assele, Samson

AU - Gillessen, Silke

AU - International Germ Cell Cancer Classification Update Consortium

PY - 2021/5/10

Y1 - 2021/5/10

N2 - PURPOSE: The classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has been a major advance in the management of germ-cell tumors, but relies on data of only 660 patients with seminoma treated between 1975 and 1990. We re-evaluated this classification in a database from a large international consortium.MATERIALS AND METHODS: Data on 2,451 men with metastatic seminoma treated with cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013 were collected from 30 institutions or collaborative groups in Australia, Europe, and North America. Clinical trial and registry data were included. Primary end points were progression-free survival (PFS) and overall survival (OS) calculated from day 1 of treatment. Variables at initial presentation were evaluated for their prognostic impact. Results were validated in an independent validation set of 764 additional patients.RESULTS: Compared with the initial IGCCCG classification, in our modern series, 5-year PFS improved from 82% to 89% (95% CI, 87 to 90) and 5-year OS from 86% to 95% (95% CI, 94 to 96) in good prognosis, and from 67% to 79% (95% CI, 70 to 85) and 72% to 88% (95% CI, 80 to 93) in intermediate prognosis patients. Lactate dehydrogenase (LDH) proved to be an additional adverse prognostic factor. Good prognosis patients with LDH above 2.5× upper limit of normal had a 3-year PFS of 80% (95% CI, 75 to 84) and a 3-year OS of 92% (95% CI, 88 to 95) versus 92% (95% CI, 90 to 94) and 97% (95% CI, 96 to 98) in the group with lower LDH.CONCLUSION: PFS and OS in metastatic seminoma significantly improved in our modern series compared with the original data. The original IGCCCG classification retains its relevance, but can be further refined by adding LDH at a cutoff of 2.5× upper limit of normal as an additional adverse prognostic factor.

AB - PURPOSE: The classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has been a major advance in the management of germ-cell tumors, but relies on data of only 660 patients with seminoma treated between 1975 and 1990. We re-evaluated this classification in a database from a large international consortium.MATERIALS AND METHODS: Data on 2,451 men with metastatic seminoma treated with cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013 were collected from 30 institutions or collaborative groups in Australia, Europe, and North America. Clinical trial and registry data were included. Primary end points were progression-free survival (PFS) and overall survival (OS) calculated from day 1 of treatment. Variables at initial presentation were evaluated for their prognostic impact. Results were validated in an independent validation set of 764 additional patients.RESULTS: Compared with the initial IGCCCG classification, in our modern series, 5-year PFS improved from 82% to 89% (95% CI, 87 to 90) and 5-year OS from 86% to 95% (95% CI, 94 to 96) in good prognosis, and from 67% to 79% (95% CI, 70 to 85) and 72% to 88% (95% CI, 80 to 93) in intermediate prognosis patients. Lactate dehydrogenase (LDH) proved to be an additional adverse prognostic factor. Good prognosis patients with LDH above 2.5× upper limit of normal had a 3-year PFS of 80% (95% CI, 75 to 84) and a 3-year OS of 92% (95% CI, 88 to 95) versus 92% (95% CI, 90 to 94) and 97% (95% CI, 96 to 98) in the group with lower LDH.CONCLUSION: PFS and OS in metastatic seminoma significantly improved in our modern series compared with the original data. The original IGCCCG classification retains its relevance, but can be further refined by adding LDH at a cutoff of 2.5× upper limit of normal as an additional adverse prognostic factor.

U2 - 10.1200/JCO.20.03292

DO - 10.1200/JCO.20.03292

M3 - SCORING: Journal article

C2 - 33729863

VL - 39

SP - 1553

EP - 1562

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 14

ER -